BioCryst Pharmaceuticals (BCRX) Stock Analysis & AI Equity Report
BioCryst Pharmaceuticals (BCRX) overview
BioCryst Pharmaceuticals (BCRX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 875m and operating profit of USD 341m; the year-end share price was 7.80 USD and market capitalisation was USD 1,662m. BioCryst Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get BioCryst Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals develops and commercializes medicines for hereditary angioedema and other rare diseases. Its marketed products include ORLADEYO, an oral therapy for preventing hereditary angioedema attacks, and peramivir injection products for influenza. The company is also developing oral small molecule and injectable protein therapeutics for rare disease conditions, serving patients and healthcare markets.
Generate the BioCryst Pharmaceuticals report
BioCryst Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for BioCryst Pharmaceuticals and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on BioCryst Pharmaceuticals
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.